AC
Alicia Michelle Chenoweth
King's College London, Burnet Institute
Research areas: Medicine · Oncology · Monoclonal and Polyclonal Antibodies Research · Breast Cancer Treatment Studies · HER2/EGFR in Cancer Research
0000-0002-2736-9268
Employment
-
King's College London Research Associate2019 - Present
-
Burnet Institute PhD Student2014 - 2019
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (96)
- Antibodies to watch in 2026 Save
- An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer Save
- Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test Save
- Antibody-drug conjugate design and mechanisms of action for cancer treatment Save
- Tuning antibody stability and function by rational designs of framework mutations Save
- An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Data from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 6 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Figure 8 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Supplementary Figure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Supplementary Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Supplementary Figure 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Supplementary Figure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save
- Supplementary Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer Save